New data on Shionogi’s COVID-19 treatment ensitrelvir
Japanese drugmaker Shionogi (TYO: 4507) announced that the newly-obtained clinical data for the novel COVID-19 oral antiviral Xocova (ensitrelvir fumaric acid) were presented at the joint conference of the 98th Annual Meeting of the Japanese Association for Infectious Diseases and the 72nd Annual Meeting of the Japanese Society of Chemotherapy, held in Japan from June 27 to 29, 2024.
Xocova obtained emergency regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) in Japan for the indication of SARS-CoV-2 infection in November 2022.
However, in May this year, Shionogi revealed that the Phase III study (SCORPIO-HR) with ensitrelvir did not meet its primary endpoint of a statistically-significant reduction in time to sustained resolution (symptoms completely absent for at least two days) of 15 common COVID-19 related symptoms. So the latest, positive, study is valuable news for the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze